Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H20NO3PS |
Molecular Weight | 361.395 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOP(=O)(CC1=CC=C(C=C1)C2=NC3=CC=CC=C3S2)OCC
InChI
InChIKey=FVYRUSCZCWSFLT-UHFFFAOYSA-N
InChI=1S/C18H20NO3PS/c1-3-21-23(20,22-4-2)13-14-9-11-15(12-10-14)18-19-16-7-5-6-8-17(16)24-18/h5-12H,3-4,13H2,1-2H3
Fostedil (KB-944) is a phosphonic acid derivative with potent vasodilator activity. KB-944 has been demonstrated to produce long lasting coronary vasodilator and hypotensive effects in conscious and anesthetized dogs; increase coronary blood flow in isolated, blood perfused heart preparations of dogs; and reduce systemic pressure in conscious normotensive and hypertensive rats. Slow channel calcium entry blockade is thought to contribute to the vasodilator activity of KB-944. Fostedil is longer acting in hypertensive animals than either nifedipine or diltiazem suggesting a potential clinical advantage for this compound. Unexpectedly, fostedil was shown to produce atrial fibrillation in 3 of 10 hypertensive patients in a placebo controlled study. Fostedil had been in phase II clinical trials for the treatment of angina pectoris. However, this research has been discontinued.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3701791
Curator's Comment: Kanebo was a subsidiary of Akzo Nobel http://en.pharmacodia.com/web/drug/1_9136.html
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.33 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6542139 |
12 mg/kg single, oral dose: 12 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
FOSTEDIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.33 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6542139 |
12 mg/kg single, oral dose: 12 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
FOSTEDIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
25.88 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6542139 |
12 mg/kg single, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
FOSTEDIL plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6542139 |
12 mg/kg single, oral dose: 12 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
FOSTEDIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6542139 |
12 mg/kg single, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
FOSTEDIL plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6542139 |
12 mg/kg single, oral dose: 12 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
FOSTEDIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.294 |
unhealthy n = 20 Health Status: unhealthy Condition: coronary heart disease Sex: M+F Food Status: UNKNOWN Population Size: 20 Sources: Page: p.294 |
Disc. AE: Angina... AEs leading to discontinuation/dose reduction: Angina (5%) Sources: Page: p.294 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Angina | 5% Disc. AE |
200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.294 |
unhealthy n = 20 Health Status: unhealthy Condition: coronary heart disease Sex: M+F Food Status: UNKNOWN Population Size: 20 Sources: Page: p.294 |
PubMed
Title | Date | PubMed |
---|---|---|
Antihypertensive effect of KB-944, a new calcium antagonist, in conscious normotensive and hypertensive rats. | 1982 |
|
A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris. | 1987 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3902675
100 mg once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4062434
Fostedil (10(-5)-10(-4) M) decreased the action potential duration measured at 30% repolarization and hyperpolarized the resting membrane potential in ventricular trabeculae of the dog heart. In single ventricular cells of the guinea-pig heart, Fostedil (10(-4) M) abolished the slow inward current and produced an outward shift of the late current measured at the end of 200 msec clamp pulse.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C83723
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
75889-62-2
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
DTXSID70226811
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
U-58
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL39516
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
53421
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
SUB07807MIG
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
100000080463
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
D41WS786UL
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
Fostedil
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY | |||
|
5468
Created by
admin on Sat Dec 16 16:31:45 GMT 2023 , Edited by admin on Sat Dec 16 16:31:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY